Lafutidine

Research use only, not for human use.

Lafutidine, a newly developed histamine H(2)-receptor antagonist, inhibits gastric acid secretion.

Lafutidine, a newly developed histamine H(2)-receptor antagonist, inhibits gastric acid secretion.(In Vitro):Lafutidine exhibits gastric mucosal protective action mediated by capsaicin-sensitive afferent neurons, in addition to a potent antisecretory effect.Lafutidine (0.1-10 μM) significantly augments the periarterial nerve stimulation (PNS, 1 Hz) induced-vasodilation in a concentration-dependent manner in rat perfused mesenteric vascular beds.(In Vivo):Lafutidine (3-30 mg/kg; p.o.; twice daily; for 6 days) dose-dependently reduces the severity of dextran sulfate Na (DSS)-induced colitis and significantly mitigates changes in the colon length and myeloperoxidase (MPO) activity.

Lafutidine exhibits gastric mucosal protective action mediated by capsaicin-sensitive afferent neurons, in addition to a potent antisecretory effect.Lafutidine (0.1-10 μM) significantly augments the periarterial nerve stimulation (PNS, 1 Hz) induced-vasodilation in a concentration-dependent manner in rat perfused mesenteric vascular beds.

Lafutidine (3-30 mg/kg; p.o.; twice daily; for 6 days) dose-dependently reduces the severity of dextran sulfate Na (DSS)-induced colitis and significantly mitigates changes in the colon length and myeloperoxidase (MPO) activity. Animal Model:Male Wistar rats (180-200 g)Dosage:3 mg/kg, 10 mg/kg, 30 mg/kg Administration:Oral administration, twice daily, for 6 daysResult:Reduced the severity of DSS-induced ulcerative colitis in a dose-dependent manner.

——

Endocrinology/Hormones

5-HT Receptor

HT

Metabolic Disease

——

118288-08-7

431.55

C22H29N3O4S

>98% (HPLC)

Ethanol: 13 mg/mL (30.12 mM); DMSO: 86 mg/mL (199.28 mM)

C1CCN(CC1)CC2=CC(=NC=C2)OC/C=C\CNC(=O)CS(=O)CC3=CC=CO3

——

(-20℃)

With Ice Pack

≥ 2 years